全文获取类型
收费全文 | 2538篇 |
免费 | 244篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 87篇 |
妇产科学 | 60篇 |
基础医学 | 321篇 |
口腔科学 | 62篇 |
临床医学 | 366篇 |
内科学 | 557篇 |
皮肤病学 | 28篇 |
神经病学 | 196篇 |
特种医学 | 307篇 |
外科学 | 174篇 |
综合类 | 60篇 |
预防医学 | 221篇 |
眼科学 | 52篇 |
药学 | 120篇 |
中国医学 | 5篇 |
肿瘤学 | 146篇 |
出版年
2023年 | 20篇 |
2022年 | 14篇 |
2021年 | 45篇 |
2020年 | 25篇 |
2019年 | 33篇 |
2018年 | 71篇 |
2017年 | 37篇 |
2016年 | 56篇 |
2015年 | 47篇 |
2014年 | 71篇 |
2013年 | 88篇 |
2012年 | 104篇 |
2011年 | 135篇 |
2010年 | 88篇 |
2009年 | 107篇 |
2008年 | 96篇 |
2007年 | 94篇 |
2006年 | 104篇 |
2005年 | 93篇 |
2004年 | 79篇 |
2003年 | 81篇 |
2002年 | 87篇 |
2001年 | 41篇 |
2000年 | 41篇 |
1999年 | 47篇 |
1998年 | 61篇 |
1997年 | 76篇 |
1996年 | 81篇 |
1995年 | 62篇 |
1994年 | 63篇 |
1993年 | 61篇 |
1992年 | 40篇 |
1991年 | 29篇 |
1990年 | 41篇 |
1989年 | 65篇 |
1988年 | 58篇 |
1987年 | 47篇 |
1986年 | 52篇 |
1985年 | 43篇 |
1984年 | 31篇 |
1983年 | 25篇 |
1982年 | 31篇 |
1981年 | 20篇 |
1979年 | 14篇 |
1978年 | 16篇 |
1977年 | 19篇 |
1976年 | 16篇 |
1975年 | 15篇 |
1974年 | 16篇 |
1971年 | 17篇 |
排序方式: 共有2790条查询结果,搜索用时 15 毫秒
1.
Rian M. Hasson Kayla A. Fay Joseph D. Phillips Timothy M. Millington David J. Finley 《American journal of surgery》2021,221(4):725-730
BackgroundRural populations face many health disadvantages compared to urban areas. There is a critical need to better understand the current lung cancer screening landscape in these communities to identify targeted areas to improve the impact of this proven tool.MethodsData from the County Health Rankings of New Hampshire and Vermont was reviewed for population density, distribution of adult smokers, and level of education compared to the distribution of Lung Cancer Screening Facilities throughout these two states.ResultsScreening programs in southern counties of Vermont with lower levels of education have decreased access. In New Hampshire, there are no programs within 30 miles of the areas with the largest distribution of smokers, and decreased access in some areas with the lowest levels of education.ConclusionsImproving equitable access to high-quality screening services in rural regions and the creation of targeted interventions to address decreased access in areas of high tobacco use and low education is vital to decreasing the incidence of latestage presentations of lung cancer within these populations. 相似文献
2.
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
5.
6.
7.
8.
9.
10.
The case notes of 34 patients whose sera contained an antibody giving an unusual immunofluorescent staining pattern were reviewed.
This antibody designated M2(1) gave a slightly different pattern of staining on composite sections of rat liver, kidney and
stomach from the primary biliary cirrhosis associated M2 antimitochondrial antibody. Anaemia was present in 10 patients, endocrine
disease in 7 patients and autoimmune liver disease in 6 patients. We did not find the presence of M2(l) antibody to be of
specific diagnostic significance. Although the M2(l) antibody is rare, caution is required in order to avoid confusion between
this antibody and the M2 antimitochondrial antibody of primary biliary cirrhosis. 相似文献